Fagron N.V. Logo

Fagron N.V.

FAGR | BR

Overview

Corporate Details

ISIN(s):
BE0003874915
LEI:
549300TRKRUFK2RRG779
Country:
Belgium
Address:
Venecoweg 20A, 9810 Nazareth
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Fagron N.V. is a global pharmaceutical company that specializes in pharmaceutical compounding to advance personalized medicine. The company focuses on optimizing and innovating customized pharmaceutical care for hospitals, pharmacies, clinics, and prescribers. Fagron develops and supplies a wide range of products, including pharmaceutical raw materials, active pharmaceutical ingredients (APIs), excipients, and innovative compounding vehicles such as Pentravan® (a transdermal base) and SyrSpend® (oral suspending vehicles). By providing these solutions, Fagron empowers healthcare professionals to prepare sterile and non-sterile medications tailored to the unique needs of individual patients, thereby widening the therapeutic scope of prescribers worldwide.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Fagron N.V.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-31 08:22
Earnings Release
Fagron delivers strong performance with 11% topline growth and 12% increase in …
English 209.5 KB
2025-07-31 08:22
Earnings Release
Fagron delivers strong performance with 11% topline growth and 12% increase in …
English 987.2 KB
2025-07-31 08:21
Earnings Release
Fagron levert sterke resultaten met een omzetgroei van 11% en 12% stijging van …
Dutch 205.8 KB
2025-07-31 08:21
Earnings Release
Fagron levert sterke resultaten met een omzetgroei van 11% en 12% stijging van …
Dutch 993.4 KB
2025-07-31 07:00
Interim Report
Fagron - IFS 30-07-2025 EN.pdf
English 1.6 MB
2025-07-31 07:00
Interim Report
Fagron - IFS 30-07-2025 NL.pdf
Dutch 1.6 MB
2025-07-31 07:00
Earnings Release
Fagron - H1 2025 PR EN.pdf
English 987.2 KB
2025-07-31 07:00
Earnings Release
Fagron - H1 2025 PR NL.pdf
Dutch 993.4 KB
2025-07-21 07:39
Major Shareholding Notification
Disclosure of notification received from Alychlo
Dutch 479.4 KB
2025-07-21 07:39
Major Shareholding Notification
Disclosure of notification received from Alychlo
English 489.9 KB
2025-07-18 18:00
Major Shareholding Notification
250718_Fagron transparency Alychlo_PR_ENG.pdf
English 489.9 KB
2025-07-18 18:00
Declaration of Voting Results & Voting Rights Announcements
250718_Fagron transparency Alychlo_PR_NL.pdf
Dutch 479.4 KB
2025-06-09 08:27
Declaration of Voting Results & Voting Rights Announcements
Fagron increases share capital through exercise subscription rights
English 93.1 KB
2025-06-09 08:27
Share Issue/Capital Change
Fagron increases share capital through exercise subscription rights
Dutch 398.4 KB
2025-06-06 19:00
Share Issue/Capital Change
250606 - Press release increase share capital 6 June 2025.pdf
English 93.1 KB

Automate Your Workflow. Get a real-time feed of all Fagron N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Fagron N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-23 Pulido Andrew Executive member Sell 85,000 1,803,351.50 EUR
2025-05-22 Pulido Andrew Executive member Buy 85,000 1,617,550.00 EUR
2025-05-02 De Jong Cornelia Neeltje Board Sell 12,689 263,834.55 EUR
2025-04-30 De Jong Cornelia Neeltje Board Sell 229 4,660.15 EUR
2025-04-29 De Jong Cornelia Neeltje Board Sell 10,000 201,500.00 EUR
2025-03-28 J. Verlinden Other Buy 24,551 453,702.48 EUR
2025-03-28 J. Verlinden Other Sell 17,930 344,047.56 EUR
2025-03-27 Padilla Rafael Board Buy 78,469 1,450,107.12 EUR
2025-03-27 De Jong Cornelia Neeltje Board Buy 45,418 839,324.64 EUR
2025-02-21 Bakker Vera Executive member Buy 773 15,000.00 EUR

Peer Companies

Company Country Ticker View
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Makes saliva-based diagnostics accessible for at-home & pro health & drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AGRONOMICS LIMITED Logo Isle of Man ANIC
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK